SynthesisFrontiers in medicine2026
Bibliometric analysis of stereotactic ablative radiotherapy for oligometastases.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oligometastases, an intermediate stage of metastatic cancer, are increasingly managed with Stereotactic Ablative Radiotherapy (SABR), a highly precise local therapy representing a pivotal paradigm shift for improving patient outcomes. This study aimed to comprehensively map the research landscape of SABR for oligometastases. Methods: We conducted a cross-sectional bibliometric analysis of 1,066 publications from the Web of Science Core Collection and PubMed from January 1, 2006, to December 31, 2025. Publication trends, key contributors, and collaboration networks were quantified and visualized using bibliometrix, VOSviewer, and CiteSpace. Results: Our results indicate significant and consistent growth in this field since 2006, with the United States, Italy, and Canada as leading countries, and Humanitas University among the most productive institutions, alongside key authors like Marta Scorsetti. Influential research appeared in leading oncology journals, and keyword analysis identified hotspots in cancer types, metastatic sites, treatment strategies, and the integration of immunotherapy and AI. Landmark clinical trials (e.g., SABR-COMET, ORIOLE) were highly cited. Conclusion: This comprehensive overview underscores the rapid development, international collaboration, and critical research directions within the field, highlighting SABR's translational potential and providing a foundation for identifying future research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.